Trials / Recruiting
RecruitingNCT06754345
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.
Detailed description
Participants with cancer underwent 68Ga-NK224 PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax) and mean SUV (SUVmean). In addition, the PD-L1 expression of lesions was confirmed by histopathological analyzing. The quantitative parameters of 68Ga-NK224 PET/CT were compared with histopathological result to evaluate the diagnostic efficacy.
Conditions
Timeline
- Start date
- 2023-12-31
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-12-31
- Last updated
- 2026-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06754345. Inclusion in this directory is not an endorsement.